


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): ~~A compound~~ Compounds of the formula I



in which

- D denotes a mono- or bicyclic aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂ or -C≡CH,
- X denotes NR³ or O,
- Y denotes O, S, NH, N-CN or N-NO₂,
- R¹ denotes H, Ar, Het, ~~or~~ cycloalkyl, ~~or~~
- R¹ may also be A [I.] which is optionally ~~may be~~ mono-, di- or trisubstituted by OR², SR², S(O)_mR², SO₂N(R²)₂, SO₃R², S(=O)(=NR²)R², NR²SO₂R², OSO₂R², OSO₂N(R²)₂, N(R²)₂, CN, COOR², CON(R²)₂, Ar, Het or cycloalkyl,
- E denotes CH or N,
- Z is absent or denotes a (CH₂)_q group, in which one or two CH₂ groups may be replaced by N, O and/or S atoms and/or by a -CH=CH- group and which is unsubstituted or monosubstituted by carbonyl oxygen (=O),
- Z' is absent or denotes a (CH₂)_q group, in which one or two CH₂ groups may be replaced by N, O and/or S atoms and/or by a -CH=CH- group and which is unsubstituted or monosubstituted by carbonyl oxygen (=O),
- Q is absent or denotes O, NR², C=O, SO₂ or C(R²)_n,
- R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- R³ denotes H or A,

- R^1, R^4 each, independently of one another, is absent or denote A, OH or OA, or R^1 and R^4 together also denote methylene or ethylene,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by =O, =S, =NH, =NR³, =NOR³, =NCOR³, =NCOOR³, =NOCOR³, R³, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂NR² and/or S(O)_nA,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,
- Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²SO₂A, COR², SO₂N(R²)₂, -[C(R³)₂]_n-COOR², -O-[C(R³)₂]_o-COOR², SO₃H or S(O)_nA,
- Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R³)₂]_n-COOR³ or -O-[C(R³)₂]_o-COOR³,
- Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen (=O), =S, =N(R²)₂, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-OR², -[C(R³)₂]_n-N(R³)₂, NO₂, CN, -[C(R³)₂]_n-COOR², -[C(R³)₂]_n-CON(R²)₂, -[C(R³)₂]_n-NR²COA, NR²CON(R²)₂, -[C(R³)₂]_n-NR²SO₂A, COR², SO₂N(R²)₂ and/or S(O)_nA,
- Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂ and/or S(O)_nA,
- Hal denotes F, Cl, Br or I,
- m denotes 1 or 2,
- n denotes 0, 1 or 2,
- o denotes 1, 2 or 3,

p denotes 1, 2, 3, 4 or 5,

q, q' each, independently of one another, denote 0, 1, 2, 3 or 4, where at least one of the groups Z or Z' is present, and

$0 < q + q' \leq 6$,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR² or COOR², or pyridyl which is unsubstituted or monosubstituted by Hal, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

3. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which D denotes phenyl which is monosubstituted by Hal, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

4. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which R² denotes H or A, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

5. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which T denotes

a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), or

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OR² or NR²COA, or a monocyclic unsubstituted, saturated carbocycle, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

6. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which Q is absent or denotes O or CH₂, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

7. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², NR²COA, SO₂A, SO₂NH₂, COOR² or CN, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

8. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ according to Claim 1 in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³ or NR³COA, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

9. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which R¹ denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR², ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

10. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which R¹ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR³, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

11. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

12. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which Y denotes O, ~~and pharmaceutically-usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

13. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which X denotes NR³ or O, ~~and R³ denotes H, and pharmaceutically-usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

14. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which Z [[,]] ~~and Z' each~~ denote ethylene, ~~and pharmaceutically-usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

15. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which T denotes
a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle, ~~and pharmaceutically-usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

16. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, ~~and pharmaceutically-usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

17. (Currently Amended): A compound ~~Compounds~~ according to Claim 1₁ in which
D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR² or COOR², or pyridyl which is unsubstituted or monosubstituted by Hal,

X denotes NR^3 or O,
 Y denotes O,
 R^1 denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR^2 ,
 E denotes CH or N,
 Z, Z' each denote ethylene,
 Q is absent or denotes O or CH_2 ,
 R^2 denotes H or A,
 R^3 denotes H or A,
 $\text{R}^4, \text{R}^{4'}$ each, independently of one another, is absent or denote A, OH or OA, or R^4
 and $\text{R}^{4'}$ together ~~also~~ denote methylene or ethylene,
 T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or
 O atoms, which may be unsubstituted or mono- or disubstituted by A or
 carbonyl oxygen ($=\text{O}$), phenyl which is unsubstituted or mono-, di- or
 trisubstituted by Hal, OH, OA or NHCOA , or a monocyclic unsubstituted,
 saturated carbocycle,
 A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H
 atoms may be replaced by F,
 Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal,
 A, OR^2 , NR^2COA , SO_2A , SO_2NH_2 , COOR^2 or CN,
 Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle
 having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or
 disubstituted by A or carbonyl oxygen ($=\text{O}$),
 Hal denotes F, Cl, Br or I, and
 p denotes 1, 2, 3, 4 or 5, and
~~pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

18. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in
 which

D denotes phenyl which is monosubstituted by Hal,
 X denotes NR^3 or O,

Y denotes O,

R¹ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR³,

R^{3'} denotes H,

E denotes CH or N,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH₂,

R² denotes H or A,

R³ denotes H or A,

R⁴, R^{4'} each, independently of one another, is absent or denote A, OH or OA, or R⁴ and R^{4'} together ~~also~~ denote methylene or ethylene,

T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

19. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes NR^{3'} or O,

Y denotes O,

R¹ denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,

or

A, which may be monosubstituted by OR³,

R³ denotes H or A,

R^{3'} denotes H,

E denotes CH or N,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH₂,

R² denotes H or A,

R³ denotes H or A,

R⁴, R^{4'} each, independently of one another, is absent or denote A, OH or OA, or R⁴ and R^{4'} together also denote methylene or ethylene,

T denotes piperidinyl, piperazinyl, pyridinyl, 2-oxopiperidin-1-yl, 2-oxopiperidin-4-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxo-piperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, pyridazinyl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, where the radicals may additionally be monosubstituted by A, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I, and

pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

20. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,
 X denotes NR^3 or O,
 Y denotes O,
 R^1 denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,
 or
 A, which may be monosubstituted by OR^3 ,
 R^3 denotes H or A,
 $\text{R}^{3'}$ denotes H,
 E denotes CH or N,
 Z denotes ethylene,
 Z' denotes ethylene,
 Q is absent or denotes O or CH_2 ,
 R^2 denotes H or A,
 R^3 denotes H or A,
 $\text{R}^4, \text{R}^{4'}$ is absent, or R^4 and $\text{R}^{4'}$ together also denote methylene or ethylene,
 T denotes piperidin-1- or 4-yl, piperazinyl, morpholin-4-yl,
 each of which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O),
 or unsubstituted cyclohexyl,
 A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and
 Hal denotes F, Cl, Br or I, ~~and~~
~~pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

21. (Currently Amended): A compound according Compounds according to Claim 1, wherein said compound is selected from:

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidiny-1-yl)-2-oxo-1-phenylethyl]-urea,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxo-1-phenylethyl}urea ,

(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-3-ylmethylpiperazin-1-yl)-ethyl]urea bistrifluoroacetate,

(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(4-pyridin-4-yl)piperazin-1-yl]-methanoyl}propyl}urea bistrifluoroacetate,

(R,R)-1-(4-chlorophenyl)-3-(2-methoxy-1-[1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methanoyl}propyl)urea bistrifluoroacetate,

(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(1'-methyl-4,4'-bipiperidinyl-1-yl)-methanoyl}propyl}urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[1-(4-pyridin-4-ylpiperazine-1-carbonyl)butyl]urea,

(R)-1-(4-chlorophenyl)-3-{2-[4-hydroxy-4-(4-methoxyphenyl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea,

(R)-1-(4-chlorophenyl)-3-{2-[4-(2-methoxyphenyl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea,

(R)-N-[4-(1-{2-[3-(4-chlorophenyl)ureido]-2-phenylethanoyl}piperidin-4-ylmethyl)-phenyl]acetamide,

(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-[4-(1-phenylmethanoyl)piperidin-1-yl)-ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]urea,

(R)-1-[2-(4-benzylpiperazin-1-yl)-2-oxo-1-phenylethyl]-3-(4-chlorophenyl)urea,

(R)-1-(4-chlorophenyl)-3-{2-[5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-oxo-1-phenylethyl}urea,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea,

(R,S)-1-[2-(3-benzylpiperidin-1-yl)-2-oxo-1-phenylethyl]-3-(4-chlorophenyl)urea,

(S,S)-1-(4-chlorophenyl)-3-{2-hydroxy-1-[1-(4-pyridin-4-ylpiperazin-1-yl)-methanoyl]propyl}urea,

(S,S)-1-(4-chlorophenyl)-3-(2-hydroxy-1-{1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methanoyl}propyl)urea,

(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(4-pyridin-3-ylmethylpiperazin-1-yl)-methanoyl]propyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]urea bistrifluoroacetate,

(R,R)-1-(4-chlorophenyl)-3-(1-{1-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-methanoyl}-2-methoxypropyl)urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R)-1-(2,4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-[2,4,4'-bipiperidinyl-1-yl]-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)-urea hydrochloride,

(R)-1-(2,4,4'-bipiperidinyl-1-yl)-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl]urea trifluoroacetate,

1-[2-[1,4']bipiperidinyl-1'-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)-urea,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl]-urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidiny-1'-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-cyclohexylpiperazin-1-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-cyclohexylpiperazin-1-yl)-2-oxo-1-phenylethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{1-(4-hydroxyphenyl)-2-[4-(4-methylpiperazin-1-yl)-piperidin-1-yl]-2-oxoethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl]urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidiny-1'-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-cyclohexylpiperazin-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-thiophen-2-ylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidiny-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[2-(4,4'-bipiperidiny-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]-urea,

(R)-1-(4-chlorophenyl)-3-[1-(2-chlorophenyl)-2-(1'-methyl-2'-oxo-4,4'-bipiperidiny-1-yl)-2-oxoethyl]urea,

(R)-1-(4-chlorophenyl)-3-[1-phenyl-2-(1'-methyl-2'-oxo-4,4'-bipiperidiny-1-yl)-2-oxoethyl]urea,

2-(1'-methyl-4,4'-bipiperidiny-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-carbamate,

2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl (R)-(4-chlorophenyl)carbamate,

2-4,4'-bipiperidinyl-1-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-
carbamate hydrochloride,

2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate
hydrochloride,

1-(2-chlorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate trifluoroacetate,

1-(2-chlorophenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-
carbamate trifluoroacetate,

2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-
carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate
trifluoroacetate,

1-(2-chlorophenyl)-2-(4-cyclohexylpiperazin-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)-
carbamate trifluoroacetate,

2-(4-cyclohexylpiperazin-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate
trifluoroacetate,

1-(2-chlorophenyl)-2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxoethyl (R)-(4-
chlorophenyl)carbamate bistrifluoroacetate,

2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl (R)-(4-
chlorophenyl)carbamate bistrifluoroacetate,

1-(2,3-difluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate,

1-(2-fluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate,

1-(2-methoxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,
including mixtures thereof in all ratios.

22. (Currently Amended): A process ~~Process~~ for the preparation of a compound
~~compounds of the formula I according to Claim 1, said process comprising and~~
~~pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that~~


a) for the preparation of compounds ~~of the formula I~~

~~in which~~

X denotes NH and

Y denotes O,

reacting a compound of the formula II



~~in which~~

~~R¹, R⁴, R⁴', E, Q, T, Z and Z' have the meanings indicated in Claim 1,~~

~~is reacted~~ with a compound of the formula III



~~in which~~



~~D has the meaning indicated in Claim 1,~~

or

b) for the preparation of compounds ~~of the formula I~~

~~in which~~

X and Y denote O,



X and Y denote O, and

~~R⁺ and D have the meanings indicated in Claim 1.~~

pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally one or more excipients and/or adjuvants.

26. (Currently Amended): A pharmaceutical composition comprising a Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

27. (Currently Amended): A method of treating a patient suffering from Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, said method comprising administering to said patient an effective amount of a compound according to claim 1.

28. (Currently Amended): A kit comprising Set (kit) consisting of a first and second separate packs of, said first pack containing (a) an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and said second pack containing (b) an effective amount of a further medicament active ingredient.

29. (Currently Amended): A method according to claim 27, further comprising administering to said patient Use of compounds of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios;

for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases;

in combination with at least one further medicament active ingredient.

30. (New): A compound according to claim 1, wherein E is or N, Z and Z' are each ethylene, and Q is absent.

31. (New): A compound according to claim 30, wherein X is NR^3 and Y is O.

32. (New): A compound according to claim 30, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

33. (New): A compound according to claim 31, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

34. (New): A compound according to claim 30, wherein R^1 is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

35. (New): A compound according to claim 33, wherein R^1 is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

36. (New): A compound according to claim 30, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

37. (New): A compound according to claim 35, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.